In conclusion, we developed a novel and potential therapeutic T cell engager bispecific antibody Vγ2 x PD-L1, which caused Vγ2Vδ2 T cells to destroy PD-L1 expressing tumor cells efficiently and selectively. The gene discussed is CD274; the disease is neoplasm.